Research ArticleClinical Investigation
O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma
Markus Hutterer, Martha Nowosielski, Daniel Putzer, Dietmar Waitz, Gerd Tinkhauser, Herwig Kostron, Armin Muigg, Irene J. Virgolini, Wolfgang Staffen, Eugen Trinka, Thaddäus Gotwald, Andreas H. Jacobs and Guenther Stockhammer
Journal of Nuclear Medicine June 2011, 52 (6) 856-864; DOI: https://doi.org/10.2967/jnumed.110.086645
Markus Hutterer
Martha Nowosielski
Daniel Putzer
Dietmar Waitz
Gerd Tinkhauser
Herwig Kostron
Armin Muigg
Irene J. Virgolini
Wolfgang Staffen
Eugen Trinka
Thaddäus Gotwald
Andreas H. Jacobs
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 52, Issue 6
June 1, 2011
O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma
Markus Hutterer, Martha Nowosielski, Daniel Putzer, Dietmar Waitz, Gerd Tinkhauser, Herwig Kostron, Armin Muigg, Irene J. Virgolini, Wolfgang Staffen, Eugen Trinka, Thaddäus Gotwald, Andreas H. Jacobs, Guenther Stockhammer
Journal of Nuclear Medicine Jun 2011, 52 (6) 856-864; DOI: 10.2967/jnumed.110.086645
O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma
Markus Hutterer, Martha Nowosielski, Daniel Putzer, Dietmar Waitz, Gerd Tinkhauser, Herwig Kostron, Armin Muigg, Irene J. Virgolini, Wolfgang Staffen, Eugen Trinka, Thaddäus Gotwald, Andreas H. Jacobs, Guenther Stockhammer
Journal of Nuclear Medicine Jun 2011, 52 (6) 856-864; DOI: 10.2967/jnumed.110.086645
Jump to section
Related Articles
Cited By...
- Amino Acid PET in Neurooncology
- Amino Acid PET in Neurooncology
- MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
- Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study
- Influence of Bevacizumab on Blood-Brain Barrier Permeability and O-(2-18F-Fluoroethyl)-L-Tyrosine Uptake in Rat Gliomas
- Combined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake
- Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
- Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients
- Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-L-Tyrosine PET in Comparison to MRI
- Impact of 3,4-Dihydroxy-6-18F-Fluoro-L-Phenylalanine PET/CT on Managing Patients with Brain Tumors: The Referring Physician's Perspective
- 3'-Deoxy-3'-18F-Fluorothymidine PET and MRI for Early Survival Predictions in Patients with Recurrent Malignant Glioma Treated with Bevacizumab